Dr. David Satijn holds a PhD in Molecular Biology from the University of Amsterdam. He was a Post-Doctoral Research Fellow at the department of Immunology, University of California San Diego where he studied T and B cell development. He became an Assistant Professor at the University of Amsterdam where he worked on the role of epigenetic elements and the stable production of recombinant antibodies. In 2006, he joined Genmab and is currently supervising Target Discovery and novel Antibody Programs. Dr. David Satijn is based in Genmab Utrecht, the Netherlands and serves in the position of Assistant Director, Antibody Science.
Development of antibody drug conjugates against Tissue Factor for the treatment of solid tumors
Tissue factor (TF) is a transmembrane glycoprotein that is found over-expressed in several types of cancers. Anti-TF human monoclonal antibody-drug conjugates have been generated by conjugation to auristatins, and in vitro and in vivo efficacy was assessed. Results show that TF may be an ideal target for immunotherapy in cancer.